Sentence examples for multiple inhibitors with from inspiring English sources

The synthetic strategy was designed modularly to access multiple inhibitors with different aryl functionalities containing both the natural depsipeptide and peptide isostere variant of the macrocycle.

This was not completely expected and can be explained either by the presence of multiple inhibitors with distinct or overlapping specificities in PJ-S21 or by induction of gp120 conformational changes [ 54] resulting in blockade of both CD4 and CXCR4/CCR5 binding sites on gp120.

Yet the clinical development of therapies targeting the FGFR signalling pathway presents multiple challenges, with diverse mechanisms of pathway activation combined with multiple inhibitors of differing potency and with antibodies in preclinical development.

Both are clinically validated targets with multiple inhibitors in therapeutic use.

First, in a dilute mixture with multiple inhibitors, the partitioning calculation, to first approximation, is independent for each inhibitor species.

Overexpression of Aurora kinases A and B have been linked to genetic instability and are frequently overexpressed in solid tumors such as colorectal cancer [ 50, 51] and inhibition of aurora kinases has become an attractive therapeutic strategy with multiple inhibitors in clinical development.

Therefore, combinations of multiple inhibitors have been proposed along with the identification of key driver mutations that are specific to each patient.

A further disadvantage of the soluble NgR 310)ecto is that it only sequesters inhibitors in a one-to-one ratio whereas one aptamer could compete with the binding of multiple inhibitors (Figure S5).

Multiple FGFR inhibitors with various structural skeletons have been designed, synthesized, and evaluated.

Finally, we compare the binding affinities of multiple kinase inhibitors with the phosphorylation activity of their targets in our study.

This patient is alive with disease 66 months after the initial diagnosis, and was treated with multiple kinase inhibitors with marginal responses, including imatinib, sunitinib, sorafenib and sirolimus, and being presently on regorafenib.